Arbutus Biopharma Corp (ABUS) vs Apnimed, Inc. (APMD)

A side-by-side comparison of Arbutus Biopharma Corp and Apnimed, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$889M

$4.50HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

APMD

Apnimed, Inc.

$840M

$21.09HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

Total return — ABUS vs APMD

growth of $100 · dividends reinvested · last 1y

ABUS +5.9% (+5.9%/yr)APMD +35.9% (+35.9%/yr)APMD compounded faster over this window

ABUS APMD

Metrics side by side

Total return (annualized)

Metric	ABUS	APMD
Total return (1Y)	6.59%	N/A
Total return CAGR (3Y)	34.95%	N/A
Total return CAGR (5Y)	2.19%	N/A
Total return CAGR (10Y)	2.93%	N/A

APMD is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ABUS analysis Full APMD analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.